BT Investment Management »

Sage Therapeutics shares owned by BT Investment Management

Quarter-by-quarter ownership of Sage Therapeutics (SAGE) shares owned by BT Investment Management from 13F filings

Historical chart of BT Investment Management investment in Sage Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sage Therapeutics held by BT Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sage Therapeutics by BT Investment Management

Quarter filed Position value Share count Share price at filing
2022-12-31 $332k 8.7k 38.14

More positions owned by BT Investment Management

Unilever Spon Adr New (UL)
Henry Schein (HSIC)
Tenaris S A Sponsored Ads (TS)
Shell Spon Ads (SHEL)
Aptiv SHS (APTV)
Accenture Plc Ireland Shs Class A (ACN)
Gxo Logistics Incorporated Common Stock (GXO)
Itau Unibanco Hldg S A Spon Adr Rep Pfd (ITUB)
Globant S A (GLOB)
Microsoft Corporation (MSFT)
Anthem (ELV)
Qiagen Nv Shs New
Linde SHS
Ferguson SHS
Intercontinental Exchange (ICE)

View all positions for BT Investment Management

Top funds holding Sage Therapeutics

Vanguard Group
BlackRock
BlackRock
Bellevue Group
State Street Corporation
Morgan Stanley
Jacobs Levy Equity Management
Geode Capital Management
Palo Alto Investors
Acadian Asset Management
Goldman Sachs Group
Citadel Advisors
D. E. Shaw & Co
Federated Investors
Bank of America Corporation

View all funds holding Sage Therapeutics